Puma Biotechnology, Inc. $PBYI Shares Purchased by Acadian Asset Management LLC

Acadian Asset Management LLC raised its position in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 1.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,008,146 shares of the biopharmaceutical company’s stock after acquiring an additional 36,018 shares during the quarter. Acadian Asset Management LLC owned 4.05% of Puma Biotechnology worth $5,940,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Graham Capital Management L.P. acquired a new stake in Puma Biotechnology in the fourth quarter valued at approximately $33,000. ProShare Advisors LLC acquired a new stake in Puma Biotechnology in the fourth quarter valued at approximately $36,000. Causeway Capital Management LLC acquired a new stake in Puma Biotechnology in the first quarter valued at approximately $42,000. Price T Rowe Associates Inc. MD grew its position in Puma Biotechnology by 42.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,083 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 5,726 shares in the last quarter. Finally, PFG Investments LLC acquired a new stake in Puma Biotechnology in the first quarter valued at approximately $59,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Stock Performance

Shares of PBYI opened at $4.47 on Friday. The business’s fifty day moving average price is $4.19 and its 200 day moving average price is $3.57. Puma Biotechnology, Inc. has a 12-month low of $2.32 and a 12-month high of $6.07. The stock has a market capitalization of $225.15 million, a PE ratio of 4.56 and a beta of 1.38. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $7.00.

Insider Buying and Selling at Puma Biotechnology

In related news, Director Alessandra Cesano sold 27,000 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $3.37, for a total transaction of $90,990.00. Following the transaction, the director directly owned 41,850 shares in the company, valued at $141,034.50. This trade represents a 39.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Alan H. Auerbach sold 25,592 shares of the firm’s stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total value of $90,339.76. Following the transaction, the chief executive officer owned 7,202,481 shares in the company, valued at $25,424,757.93. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,989 shares of company stock worth $285,351 over the last 90 days. 23.30% of the stock is currently owned by company insiders.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.